105 related articles for article (PubMed ID: 15802893)
1. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity.
Lundberg LG; Lerner R; Sundelin P; Rogers R; Folkman J; Palmblad J
Am J Pathol; 2000 Jul; 157(1):15-9. PubMed ID: 10880370
[TBL] [Abstract][Full Text] [Related]
2. Thromboembolic events, major bleeding and mortality in essential thrombocythaemia and polycythaemia vera-A matched nationwide population-based study.
Enblom-Larsson A; Renlund H; Andréasson B; Holmberg H; Liljeholm M; Själander A
Br J Haematol; 2024 May; 204(5):1740-1751. PubMed ID: 38351734
[TBL] [Abstract][Full Text] [Related]
3. MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives.
Hasselbalch HC; Bjørn ME
Mediators Inflamm; 2015; 2015():102476. PubMed ID: 26604428
[TBL] [Abstract][Full Text] [Related]
4. Synoptic Diagnostics of Myeloproliferative Neoplasms: Morphology and Molecular Genetics.
Nann D; Fend F
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298741
[TBL] [Abstract][Full Text] [Related]
5. New Perspectives on Polycythemia Vera: From Diagnosis to Therapy.
Iurlo A; Cattaneo D; Bucelli C; Baldini L
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823537
[TBL] [Abstract][Full Text] [Related]
6. Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: a Review of the Recent Literature.
Zhou A; Afzal A; Oh ST
Curr Hematol Malig Rep; 2017 Oct; 12(5):397-405. PubMed ID: 28948488
[TBL] [Abstract][Full Text] [Related]
7. Extramedullary haematopoiesis presenting with cardiac tamponade in a patient with polycythaemia vera.
Haroun F; Elkis V; Chen A; Lee E
BMJ Case Rep; 2017 Aug; 2017():. PubMed ID: 28798246
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations.
Barraco D; Cerquozzi S; Hanson CA; Ketterling RP; Pardanani A; Gangat N; Tefferi A
Blood Cancer J; 2017 Mar; 7(3):e538. PubMed ID: 28282034
[TBL] [Abstract][Full Text] [Related]
9. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12.
Srour SA; Devesa SS; Morton LM; Check DP; Curtis RE; Linet MS; Dores GM
Br J Haematol; 2016 Aug; 174(3):382-96. PubMed ID: 27061824
[TBL] [Abstract][Full Text] [Related]
10. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.
Barbui T; Thiele J; Vannucchi AM; Tefferi A
Blood Cancer J; 2015 Aug; 5(8):e337. PubMed ID: 26832847
[TBL] [Abstract][Full Text] [Related]
11. The Association Between JAK2V617F Mutation and Bone Marrow Fibrosis at Diagnosis in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms.
Arı MC; Büyüktaş D; Eşkazan AE; Ongören Aydın S; Tanrıkulu E; Başlar Z; Buyru AN; Ferhanoğlu B; Aydın Y; Tüzüner N; Soysal T
Turk J Haematol; 2012 Sep; 29(3):242-7. PubMed ID: 24744667
[TBL] [Abstract][Full Text] [Related]
12. Jak-2 positive myeloproliferative neoplasms.
Muxí PJ; Oliver AC
Curr Treat Options Oncol; 2014 Jun; 15(2):147-56. PubMed ID: 24627006
[TBL] [Abstract][Full Text] [Related]
13. [Differential diagnosis of myeloproliferative neoplasms. Quantitative NF-E2 immunohistochemistry for differentiating between essential thrombocythemia and primary myelofibrosis].
Aumann K; Frey AV; May AM; Hauschke D; Kreutz C; Marx JP; Timmer J; Werner M; Pahl HL
Pathologe; 2013 Nov; 34 Suppl 2():201-9. PubMed ID: 24196613
[TBL] [Abstract][Full Text] [Related]
14. WHO classification of myeloproliferative neoplasms (MPN): A critical update.
Kvasnicka HM
Curr Hematol Malig Rep; 2013 Dec; 8(4):333-41. PubMed ID: 24146204
[TBL] [Abstract][Full Text] [Related]
15. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.
Gisslinger H; Gotic M; Holowiecki J; Penka M; Thiele J; Kvasnicka HM; Kralovics R; Petrides PE;
Blood; 2013 Mar; 121(10):1720-8. PubMed ID: 23315161
[TBL] [Abstract][Full Text] [Related]
16. The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
Thiele J; Kvasnicka HM
Curr Hematol Malig Rep; 2009 Jan; 4(1):33-40. PubMed ID: 20425436
[TBL] [Abstract][Full Text] [Related]
17. Is it justified to perform a bone marrow biopsy examination in sustained erythrocytosis?
Thiele J; Kvasnicka HM
Curr Hematol Malig Rep; 2006 Jun; 1(2):87-92. PubMed ID: 20425337
[TBL] [Abstract][Full Text] [Related]
18. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies.
Kreft A; Büche G; Ghalibafian M; Buhr T; Fischer T; Kirkpatrick CJ
Acta Haematol; 2005; 113(2):137-43. PubMed ID: 15802893
[TBL] [Abstract][Full Text] [Related]
19. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
